Bezuclastinib

Bezuclastinib (CGT9486) is Cogent Biosciences' selective inhibitor of mutant KIT, the genetic driver behind roughly 95% of systemic mastocytosis cases. The drug is heading toward an FDA decision on December 30, 2026 for nonadvanced systemic mastocytosis, about six months from now. The registrational SUMMIT trial reported positive top-line results in July 2025, hitting its primary endpoint with a placebo-adjusted Total Symptom Score reduction of 8.91 points (24.3 vs 15.4, p=0.0002) and 87.4% of bezuclastinib patients achieving a ≥50% reduction in serum tryptase versus 0% on placebo (p<0.0001) [1][11]. FDA granted Breakthrough Therapy Designation in both the post-avapritinib non-advanced SM setting and smoldering SM [12]. Cogent is also running APEX in advanced systemic mastocytosis and PEAK, a Phase 3 combination with sunitinib in second-line gastrointestinal stromal tumors, which reported positive Phase 3 results (median PFS 16.5 vs 9.2 months) and led to an NDA submission under FDA's Real-Time Oncology Review [2][3][14]. The commercial pitch is differentiation from Blueprint Medicines' Ayvakit (avapritinib), already approved for both indolent and advanced systemic mastocytosis and tracking to $700 to $720 million in 2025 net product revenue, but carrying cognitive side effects tied to brain penetration [13]. Bezuclastinib was engineered for minimal CNS exposure, which Cogent argues will support a cleaner long-term safety profile in indolent patients who take the drug for years.

Bezuclastinib is a novel compound, not approved anywhere. The SUMMIT study (NCT05186753) is recorded in ClinicalTrials.gov as Phase 2 but is functioning as registrational, an increasingly common path in rare diseases where a controlled Phase 2 with hard biomarker endpoints can support a marketing application [1]. Cogent has confirmed FDA acceptance of the NDA with a PDUFA action date of December 30, 2026, placing the decision in late 2026, roughly six months out from this writeup [4]. SUMMIT's Part 2 top-line readout in July 2025 cleared all primary and key secondary endpoints with high statistical significance [11]. FDA granted Breakthrough Therapy Designation in October 2025 for non-advanced SM patients previously treated with avapritinib and for smoldering SM, plus a separate BTD for the GIST combination [12]. Orphan Drug Designation is also held for the indication. Two other trials matter for the franchise. APEX (NCT04996875) tests bezuclastinib monotherapy in advanced systemic mastocytosis, where Ayvakit is the relevant comparator and where Cogent reported a positive readout in 2025 [2]. PEAK (NCT05208047) is a Phase 3 trial combining bezuclastinib with sunitinib against sunitinib alone in second-line gastrointestinal stromal tumors (482 patients enrolled). It reported positive Phase 3 results in 2026, with median progression-free survival of 16.5 months for the combination versus 9.2 months for sunitinib alone, and a GIST NDA was submitted under Real-Time Oncology Review [3][14]. GIST is a larger commercial opportunity than systemic mastocytosis but a more crowded space, with GSK's IDRX-42 and several other KIT inhibitors going after the same resistant exon mutations [5]. The systemic mastocytosis launch is the near-term catalyst.

KIT is a receptor on the surface of mast cells, the immune cells that release histamine during allergic reactions. Normally KIT is an on-demand growth signal: a molecule called stem cell factor binds it, and mast cells multiply or mature in response [6]. The D816V mutation jams the switch in the on position. Once that happens, mast cells proliferate without signal, accumulate in skin, bone marrow, and gut, and release histamine and tryptase chronically. That produces the flushing, itching, GI symptoms, anaphylaxis, and bone pain that define systemic mastocytosis. Roughly 95% of patients with the disease carry this single mutation, which is why a selective drug against it works for nearly the entire population [7]. The therapeutic logic is direct. Block mutant KIT and the constant proliferation signal goes away, mast cells stop expanding, and the symptoms ease. The mechanism is validated at the highest possible bar: Blueprint Medicines' avapritinib (Ayvakit) targets the same mutation, was approved by the FDA in 2021 for advanced systemic mastocytosis and in 2023 for indolent disease, and is tracking to $700 to $720 million in 2025 net product revenue (up about 60% year over year) [8][13]. What sets bezuclastinib apart is selectivity. Avapritinib crosses into the brain, with preclinical brain-to-plasma ratios of 0.74 to 1.00 at steady state, which has caused cognitive side effects and intracranial bleeding in clinical use [7][15]. Bezuclastinib was designed to stay out of the central nervous system. Preclinical rat tissue distribution studies showed a brain-to-plasma ratio under 0.1 at clinically relevant doses, with no CNS effects in neurobehavioral studies [15]. The clinical CNS safety signal will play out in SUMMIT's long-term safety extension and the APEX dataset rather than head-to-head PK, so the differentiation is currently anchored in preclinical evidence plus a clean SM safety profile to date.

SUMMIT (NCT05186753) is the registrational study for nonadvanced systemic mastocytosis. The trial is placebo-controlled and randomized, enrolling roughly 237 patients with indolent or smoldering disease who remain symptomatic on best supportive care, and enrollment is restricted to KIT D816V-positive patients. Primary endpoint was Total Symptom Score reduction at 24 weeks, measured by a validated patient-reported instrument. Key secondary endpoints included reductions in serum tryptase (a biochemical marker of mast cell burden) and mast cell infiltrates in bone marrow [1]. Top-line Part 2 results, reported July 2025, showed a mean TSS reduction of 24.3 points on bezuclastinib versus 15.4 on placebo (placebo-adjusted 8.91 points, p=0.0002), and 87.4% of bezuclastinib patients achieved a ≥50% reduction in serum tryptase versus 0% on placebo (p<0.0001). All key secondary endpoints, including bone marrow mast cell burden and KIT D816V allele burden, also hit statistical significance [11]. The Phase 2 designation reflects size and structure, not regulatory ambition: Cogent and FDA agreed the data package supports a marketing application, which is the right read for a rare disease with a validated biomarker [4]. APEX (NCT04996875) is Phase 2 in advanced systemic mastocytosis, enrolling about 140 patients across dose-finding and expansion cohorts. This is a tougher population where survival is poor and avapritinib is already on the market. APEX met its primary and key secondary endpoints in 2025 and supports the broader regulatory and label package [2]. PEAK (NCT05208047) is the Phase 3 GIST trial, randomizing 482 second-line patients to bezuclastinib plus sunitinib versus sunitinib monotherapy. Sunitinib is the current standard of care after imatinib failure, and adding a KIT inhibitor that hits resistance mutations is the scientific bet. PEAK reported positive Phase 3 data with median PFS of 16.5 months for the combination versus 9.2 months for sunitinib alone, supporting an NDA submitted under FDA's Real-Time Oncology Review [3][14]. SARC044 (NCT06208748), a Phase 2 investigator-initiated GIST study, runs in parallel with similar design and provides supplemental evidence.

This drug is under FDA review (NDA/BLA), with a PDUFA decision date of 2026-12-30. Our estimate of 93% is the historical filing-approval rate for its area, adjusted for its rejection history (no prior Complete Response Letters). At this stage the early-trial design model no longer applies - what matters is that it reached the FDA and whether it has been rejected before.

The biggest near-term risk is regulatory. FDA could push back on the Phase 2 trial as a registrational dataset, request additional follow-up, or land on a narrower label than Cogent is pursuing. The PDUFA date is firm but the outcome is not. Safety differentiation is the entire commercial thesis, which makes it the entire commercial risk. If bezuclastinib's CNS-sparing design does not translate into a meaningfully better safety profile in the long-term safety database, the cleaner-than-Ayvakit pitch evaporates. The CNS-sparing claim is currently anchored in preclinical rat tissue distribution and neurobehavioral data [15], not a head-to-head clinical comparison, so the clinical proof will accumulate through SUMMIT's safety extension. Cognitive side effects and intracranial bleeding have been the visible concerns for avapritinib in indolent SM [9]. Efficacy risk: SUMMIT's symptom score primary endpoint is patient-reported, which carries placebo response risk in a chronic-symptom disease, although the achieved separation (24.3 vs 15.4) and the tryptase biomarker (87.4% vs 0%) give corroborating objective evidence. Commercial risk is real even in a successful approval scenario. Ayvakit has been on the market for indolent SM since 2023 and is on a $700M+ run rate in 2025, growing 61% year over year, with a stated goal of $2B annually by 2030 [13]. Switching established patients requires a clear safety and efficacy story, not just a regulatory label, and Blueprint has a substantial head start in physician relationships, patient identification, and diagnostic infrastructure. The GIST program adds optionality but also risk: the competitive set against IDRX-42 and other selective KIT inhibitors is dense [5], though PEAK's reported PFS benefit is strong. On the financing side, Cogent ended Q1 2026 with $866.4M in cash, cash equivalents, and marketable securities and guides runway into 2028, covering both potential US launches without an obvious near-term dilution overhang [16]. Q1 2026 quarterly burn was about $97M with commercial buildout, so the cushion is real but not unlimited, and a softer-than-expected launch ramp would compress the runway visibly. Note on competitor list: midostaurin is approved for advanced SM and AML, not indolent SM, so it is not a direct competitor in the SUMMIT indication.

Worth watching closely, with a clean catalyst. The December 30, 2026 PDUFA date is about six months out and is the single most consequential event in Cogent's history. With SUMMIT's positive top-line readout banked, Breakthrough Therapy Designation in hand, and APEX and PEAK both reading out positively, the binary risk has shifted from efficacy uncertainty to label scope and launch execution. Approval transforms Cogent from a single-asset clinical company into a commercial rare-disease specialist with a Phase 3 GIST program funded by NSM cash flow and an $866M cash cushion stretching into 2028 [16]. A narrow label or post-marketing commitments would compress the commercial case but not destroy it. The data point to watch before then is the long-term safety extension from SUMMIT, which is where the cognitive-side-effect differentiation story has to hold. Any signal of intracranial bleeding or persistent cognitive symptoms would gut the commercial case even if the drug is approved. Cogent's 8-K cadence signals active news flow on financing, trial updates, and FDA interactions [4]. Watch the next two earnings calls for commentary on commercial readiness, manufacturing scale, sales force ramp, and pricing strategy versus Ayvakit. The realistic check-in points are Q3 2026 (commercial prep, PEAK NDA progress, any FDA advisory committee chatter) and the PDUFA itself.